PURPOSE: Strong impact of hepatitis C virus (HCV) on normal regulation of cellular processes has been reported that could have significant implications for HCV pathogenesis. We aimed to determine the altered cellular processes during HCV infection with particular reference to advanced disease stages. METHODS: Liver biopsy specimens of chronic hepatitis C patients classified on histological basis as early (fibrosis stage 1-2) or advanced (fibrosis stage 3-4) HCV disease were studied using microarray technology (Affymetrix GeneChip™ System). For comparison, liver specimens from patients with non-viral hepatitis (NV-hepatitis) were also analyzed by microarray. Expression data generated were analyzed using software Genespring GX and Ingenuity Pathway analysis to find the association with biological functions. We further validated the microarray results using quantitative reverse transcriptase-polymerase chain reaction. RESULTS: Data analysis through Genespring software revealed that in advanced HCV (A-HCV) a total of 792 genes are differentially expressed when compared to early HCV (E-HCV) and 417 genes are differentially expressed when compared to NV-hepatitis. Most of these genes are involved in cancer, cellular growth and proliferation, and tissue morphology. Real time (RT) PCR analysis confirmed the differential expression of six of these genes. CONCLUSION: The results of this study reflect the changes taking place during the transition from early to advanced liver fibrosis, when the liver function becomes impaired and extracellular matrix deposition increases. In addition, it showed altered expression of genes with functions in cancer development, cell growth, proliferation, and cell death that might indicate high risk of cell transformation and hepatocellular carcinoma (HCC) in A-HCV disease patients.
PURPOSE: Strong impact of hepatitis C virus (HCV) on normal regulation of cellular processes has been reported that could have significant implications for HCV pathogenesis. We aimed to determine the altered cellular processes during HCV infection with particular reference to advanced disease stages. METHODS: Liver biopsy specimens of chronic hepatitis Cpatients classified on histological basis as early (fibrosis stage 1-2) or advanced (fibrosis stage 3-4) HCV disease were studied using microarray technology (Affymetrix GeneChip™ System). For comparison, liver specimens from patients with non-viral hepatitis (NV-hepatitis) were also analyzed by microarray. Expression data generated were analyzed using software Genespring GX and Ingenuity Pathway analysis to find the association with biological functions. We further validated the microarray results using quantitative reverse transcriptase-polymerase chain reaction. RESULTS: Data analysis through Genespring software revealed that in advanced HCV (A-HCV) a total of 792 genes are differentially expressed when compared to early HCV (E-HCV) and 417 genes are differentially expressed when compared to NV-hepatitis. Most of these genes are involved in cancer, cellular growth and proliferation, and tissue morphology. Real time (RT) PCR analysis confirmed the differential expression of six of these genes. CONCLUSION: The results of this study reflect the changes taking place during the transition from early to advanced liver fibrosis, when the liver function becomes impaired and extracellular matrix deposition increases. In addition, it showed altered expression of genes with functions in cancer development, cell growth, proliferation, and cell death that might indicate high risk of cell transformation and hepatocellular carcinoma (HCC) in A-HCV diseasepatients.
Authors: Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin Journal: Gastroenterology Date: 2005-12 Impact factor: 22.682
Authors: Ivan Bièche; Tarik Asselah; Ingrid Laurendeau; Dominique Vidaud; Claude Degot; Valérie Paradis; Pierre Bedossa; Dominique-Charles Valla; Patrick Marcellin; Michel Vidaud Journal: Virology Date: 2005-02-05 Impact factor: 3.616
Authors: Aileen Marshall; Simon Rushbrook; Susan E Davies; Lesley S Morris; Ian S Scott; Sarah L Vowler; Nicholas Coleman; Graeme Alexander Journal: Gastroenterology Date: 2005-01 Impact factor: 22.682
Authors: Maria W Smith; Zhaoxia N Yue; Marcus J Korth; Hao A Do; Loreto Boix; Nelson Fausto; Jordi Bruix; Robert L Carithers; Michael G Katze Journal: Hepatology Date: 2003-12 Impact factor: 17.425
Authors: Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro Journal: Infect Agent Cancer Date: 2012-03-26 Impact factor: 2.965
Authors: Alan D Radford; David Chapman; Linda Dixon; Julian Chantrey; Alistair C Darby; Neil Hall Journal: J Gen Virol Date: 2012-05-30 Impact factor: 3.891